Quick Answer
REGENEREX PHARMA, INC. reported Operating Income Loss of -$1.83 million for the year ending 2025.
- REGENEREX PHARMA, INC. showed an increase of +47.3% in Operating Income Loss from 2024 to 2025.
- This data is from REGENEREX PHARMA, INC.'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2010: -$17.8 thousand | Q3 2011: -$16.0 thousand | Q1 2016: -$21.00 | Q4 2016: -$2.2 thousand | Q1 2017: -$8.1 thousand | Q2 2017: -$17.1 thousand | Q3 2017: -$8.1 thousand | Q4 2017: -$10.3 thousand | Q2 2018: -$18.6 thousand | Q3 2018: -$4.8 thousand | Q4 2018: -$52.3 thousand | Q2 2019: -$31.1 thousand | Q3 2019: -$11.6 thousand | Q4 2019: -$12.6 thousand | Q2 2020: -$10.1 thousand | Q3 2020: -$12.0 thousand | Q4 2020: -$14.3 thousand | Q2 2021: -$11.7 thousand | Q3 2021: -$21.1 thousand | Q4 2021: -$62.0 thousand | Q2 2022: -$17.3 thousand | Q3 2022: -$21.5 thousand | Q4 2022: -$29.1 thousand | Q2 2023: -$160.2 thousand | Q3 2023: -$2.79 million | Q4 2023: -$239.4 thousand | Q2 2024: -$254.3 thousand | Q3 2024: -$258.4 thousand | Q4 2024: -$311.5 thousand | Q2 2025: -$633.8 thousand | Q3 2025: -$786.7 thousand.
- Over the full 9 years of available data (2017 to 2025), REGENEREX PHARMA, INC.'s Operating Income Loss has declined by 70,871.5%.
- Historical annual values: Fiscal year 2025: -$1.83 million | Fiscal year 2024: -$3.47 million | Fiscal year 2023: -$96.2 thousand | Fiscal year 2022: -$126.3 thousand | Fiscal year 2021: -$43.4 thousand | Fiscal year 2020: -$77.0 thousand | Fiscal year 2019: -$91.7 thousand | Fiscal year 2018: -$49.5 thousand | Fiscal year 2017: -$2.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: